C8 dihydro Ceramide (d18:0/8:0) (Synonyms: Cer(d18:0/8:0)) |
| Catalog No.GC43108 |
C8 dihydro Ceramide (d18:0/8:0) is a negative control of C8 Ceramide. C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 145774-33-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C8 dihydro Ceramide is a sphingolipid and an intermediate in the synthesis of C8 ceramide [1]. It is synthesized by the acylation of sphinganine by ceramide synthase, a process that can be inhibited by some fungal mycotoxins, such as fumonisin B1 . [2] C8 dihydro Ceramide can be converted to C8 ceramide via the introduction of a 4,5-trans double bond by dihydroceramide desaturase.[1]C8 dihydro ceramide is metabolically inactive and has been used as a negative control for the biological activity of C8 ceramide.[3]
Reference:
[1]. Michel, C., van Echten-Deckert, G., Rother, J., et al. Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide. J. Biol. Chem. 272(36), 22432-22437 (1997).
[2]. Wang, E., Norred, W.P., Bacon, C.W., et al. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. J. Biol. Chem. 266(22), 14486-14490 (1991).
[3]. Struckhoff, A.P., Bittman, R., Burow, M.E., et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J. Pharmacol. Exp. Ther. 309(2), 523-532 (2004).
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *